Conavi Medical’s Novasight Hybrid Imaging Technology for Coronary Procedures Moves Toward Commercialization With New Funding

December 15, 2021—Conavi Medical Inc. announced it has entered into agreements for over $20 million in funding to support commercialization and growth as it prepares its Novasight hybrid system for market. The company aims to raise an additional $10 million as part of an ongoing financing effort.

According to the company, the Novasight hybrid system is a new imaging platform for interventional cardiologists to use during minimally invasive heart procedures. The technology enables simultaneous and coregistered imaging of coronary arteries with both intravascular ultrasound and optical coherence tomography.

Conavi Medical noted that the Novasight hybrid system has received FDA 510(k) clearance and regulatory approval for clinical use from Health Canada and Japan’s Ministry of Health, Labor and Welfare.

Additionally, the system was featured as part of a live case performed by interventional cardiologists at New York-Presbyterian Hospital in New York, New York, and broadcast at TCT 2021, the annual Transcatheter Cardiovascular Therapeutics annual meeting held November 4-6 in Orlando, Florida.